Decoding genomic and transcriptomic signatures in colorectal cancer – next steps?
Newer technologies build on current knowledge to provide greater insights in the molecular landscape
Combinations show promise in hepatocellular carcinoma populations with poor prognosis
Encouraging data were presented for FGF19-positive tumours and those with worse hepatic function, performance status or advanced vascular invasion
Givastomig combined with immunochemotherapy shows clinical activity in metastatic gastro-oesophageal adenocarcinomas
Preliminary results revealed that the combination of claudin 18.2/4-1BB bispecific antibody with nivolumab and mFOLFOX was also well tolerated
Embracing interdisciplinary collaboration for an AI-driven oncology
ESMO now welcomes members from other disciplines to support and expedite the digital transformation of cancer care
AI-driven tool shows to improve risk stratification in colorectal cancer
A system integrating computer tomography scans and pathological markers offers promise to personalise adjuvant therapy
Advancing perioperative treatment in resectable non-small cell lung cancer
Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting
Early data presented for a biomarker-guided care of metastatic hormone-sensitive prostate cancer
Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations
Challenging ageism in gynaecological cancers
Recent research indicates that older age remains a barrier to accessing optimal treatment, despite a growing number of patients over 70 with ovarian and endometrial tumours
Data show that mirvetuximab soravtansine-gynx improves outcomes regardless of HRD status
Final analyses of the PICCOLO trial confirm the efficacy of the antibody–drug conjugate in recurrent platinum-sensitive ovarian cancer
Atezolizumab added to chemotherapy and bevacizumab is effective regardless of PD-L1 status in untreated recurrent and metastatic cervical cancer
An analysis of the BEATcc trial showed that PD-L1 is not a robust biomarker for response to treatment